Dean said the reasons were ridiculous. That's it. Would love to see the actual letter. That would go a long way to be as transparent with the shareholders as possible.
He also said, as I heared it in the CC, that the application was in a disaray.
Options? Must stay with the FDA process. Getting third party approval without shaking the NSE determination, is not all that appealing.
Market Data 
Markets 
AI
